Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 3/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646042 | 1.00 | OPRM1 (0.36) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL13647132 | 1.00 | OPRM1 (0.36) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL12835617 | 0.88 | TDP1 (0.45) | PTGS1PTGS2TDP1MEN1KMT2A | |
| SCHEMBL12762382 | 0.88 | TDP1 (0.45) | PTGS1PTGS2TDP1MEN1KMT2A | |
| SCHEMBL12056276 | 0.88 | PTGS1 (0.37) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL13686095 | 0.88 | PTGS1 (0.37) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL13686506 | 0.87 | PTGS1 (0.36) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL13783669 | 0.87 | PTGS1 (0.40) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL13880798 | 0.86 | HSD17B10 (0.39) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL16846255 | 0.86 | HSD17B10 (0.39) | OPRM1OPRD1OPRK1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441023-B2 | Peptide YY analogs | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-13 | — | — | US | disclosed |
| US-20140329742-A1 | THERAPEUTIC PEPTIDES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-7906482-B2 | Peptide YY (PYY) coupled to a group capable of reacting on a blood component so as to form a stable covalent bond, preventing said PYY peptide from crossing the blood brain barrier; improved bioavailability; reduce tumor necrosis factor (TNF)-induced acute pancreatitis | ADVANCED DIAGNOSTICS AND DISCOVERY (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080194486-A1 | Novel Anti-Obesity Agents | CONJUCHEM BIOTECHNOLOGIES, INC. (CA) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329742-A1 | THERAPEUTIC PEPTIDES | GLP1R, IAPP, GIPR | OPRM1 3558/4885OPRD1 3182/4885OPRK1 2555/4885 |
| US-20080194486-A1 | Novel Anti-Obesity Agents | GIPR, GPR119, GLP1R | OPRM1 3070/4885OPRD1 2878/4885OPRK1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.